ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 107 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,626,206 | +25.3% | 180,768 | +76.1% | 0.00% | +33.3% |
Q2 2023 | $2,895,136 | +103.5% | 102,628 | +24.1% | 0.00% | +50.0% |
Q1 2023 | $1,422,560 | -14.6% | 82,707 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $1,665,719 | -6.3% | 82,707 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $1,777,000 | -23.4% | 82,707 | +0.1% | 0.00% | -33.3% |
Q2 2022 | $2,321,000 | -52.5% | 82,607 | -22.0% | 0.00% | -25.0% |
Q1 2022 | $4,886,000 | -50.6% | 105,903 | -10.0% | 0.00% | -50.0% |
Q4 2021 | $9,888,000 | +62.6% | 117,633 | +28.9% | 0.01% | +33.3% |
Q3 2021 | $6,081,000 | +39.4% | 91,258 | +11.3% | 0.01% | +50.0% |
Q2 2021 | $4,361,000 | +243.9% | 81,966 | +180.6% | 0.00% | +300.0% |
Q1 2021 | $1,268,000 | -0.3% | 29,215 | +19.3% | 0.00% | -50.0% |
Q4 2020 | $1,272,000 | +73.1% | 24,493 | +8.9% | 0.00% | +100.0% |
Q3 2020 | $735,000 | -31.9% | 22,493 | 0.0% | 0.00% | -50.0% |
Q2 2020 | $1,080,000 | – | 22,493 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Decheng Capital Management III (Cayman), LLC | 1,824,583 | $39,520,000 | 14.33% |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,301,771 | $49,857,000 | 4.79% |
Matrix Capital Management Company, LP | 9,199,973 | $199,271,000 | 3.81% |
Integral Health Asset Management, LLC | 550,000 | $11,913,000 | 2.31% |
Avidity Partners Management LP | 4,223,100 | $91,472,000 | 1.86% |
Affinity Asset Advisors, LLC | 170,000 | $3,682,000 | 1.03% |
Eventide Asset Management | 1,861,000 | $40,309,000 | 0.79% |
Sofinnova Investments, Inc. | 583,357 | $12,636,000 | 0.74% |
Nicholas Investment Partners, LP | 158,704 | $3,438,000 | 0.32% |
SECTORAL ASSET MANAGEMENT INC | 60,000 | $1,300,000 | 0.26% |